|
1
|
Shams M, Abdallah S, Alsadoun L, Hamid YH,
Gasim R and Hassan A: Oncological horizons: The synergy of medical
and surgical innovations in cancer treatment. Cureus.
15(e49249)2023.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Wilson EM, Eskander RN and Binder PS:
Recent therapeutic advances in gynecologic oncology: A review.
Cancers (Basel). 16(770)2024.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Stefanicka-Wojtas D and Kurpas D:
Personalised medicine-implementation to the healthcare system in
europe (focus group discussions). J Pers Med.
13(380)2023.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Hassan M, Awan FM, Naz A, deAndrés-Galiana
EJ, Alvarez O, Cernea A, Fernández-Brillet L, Fernández-Martínez JL
and Kloczkowski A: Innovations in genomics and big data analytics
for personalized medicine and health care: A review. Int J Mol Sci.
23(4645)2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Akhoon N: Precision medicine: A new
paradigm in therapeutics. Int J Prev Med. 12(12)2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Zhang A, Miao K, Sun H and Deng CX: Tumor
heterogeneity reshapes the tumor microenvironment to influence drug
resistance. Int J Biol Sci. 18:3019–3033. 2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Murawski M, Jagodziński A, Bielawska-Pohl
A and Klimczak A: Complexity of the genetic background of
oncogenesis in ovarian cancer-genetic instability and clinical
implications. Cells. 13(345)2024.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Tsimberidou AM, Fountzilas E, Bleris L and
Kurzrock R: Transcriptomics and solid tumors: The next frontier in
precision cancer medicine. Semin Cancer Biol. 84:50–59.
2022.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Sadida HQ, Abdulla A, Marzooqi SA, Hashem
S, Macha MA, Akil ASA and Bhat AA: Epigenetic modifications: Key
players in cancer heterogeneity and drug resistance. Transl Oncol.
39(101821)2024.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Thankamony AP, Ramkomuth S, Ramesh ST,
Murali R, Chakraborty P, Karthikeyan N, Varghese BA, Jaikumar VS,
Jolly MK, Swarbrick A and Nair R: Phenotypic heterogeneity drives
differential disease outcome in a mouse model of triple negative
breast cancer. Front Oncol. 13(1230647)2023.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Cordani M, Dando I, Ambrosini G and
González-Menéndez P: Signaling, cancer cell plasticity, and
intratumor heterogeneity. Cell Commun Signal.
22(255)2024.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Goenka A, Khan F, Verma B, Sinha P, Dmello
CC, Jogalekar MP, Gangadaran P and Ahn BC: Tumor microenvironment
signaling and therapeutics in cancer progression. Cancer Commun
(Lond). 43:525–561. 2023.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Imodoye SO, Adedokun KA and Bello IO: From
complexity to clarity: unravelling tumor heterogeneity through the
lens of tumor microenvironment for innovative cancer therapy.
Histochem Cell Biol. 161:299–323. 2024.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Proietto M, Crippa M, Damiani C, Pasquale
V, Sacco E, Vanoni M and Gilardi M: Tumor heterogeneity:
Preclinical models, emerging technologies, and future applications.
Front Oncol. 13(1164535)2023.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wang Q, Shao X, Zhang Y, Zhu M, Wang FXC,
Mu J, Li J, Yao H and Chen K: Role of tumor microenvironment in
cancer progression and therapeutic strategy. Cancer Med.
12:11149–11165. 2023.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Garlisi B, Lauks S, Aitken C, Ogilvie LM,
Lockington C, Petrik D, Eichhorn JS and Petrik J: The complex tumor
microenvironment in ovarian cancer: Therapeutic challenges and
opportunities. Curr Oncol. 31:3826–3844. 2024.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Radu MR, Prădatu A, Duică F, Micu R,
Creţoiu SM, Suciu N, Creţoiu D, Varlas VN and Rădoi VE: Ovarian
cancer: Biomarkers and targeted therapy. Biomedicines.
9(693)2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Cooper KE, Abdallah KE, Angove RSM,
Gallagher KD and Bonham VL: Navigating access to cancer care:
Identifying barriers to precision cancer medicine. Ethn Dis.
32:39–48. 2022.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ivanisevic T and Sewduth RN: Multi-omics
integration for the design of novel therapies and the
identification of novel biomarkers. Proteomes.
11(34)2023.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Jaliffa C, Rogel U, Sen I and Singer G:
Comprehensive genomic characterization in ovarian low-grade and
chemosensitive and chemoresistant high-grade serous carcinomas.
Oncology. 1–9. 2024.PubMed/NCBI View Article : Google Scholar : (Epub ahead of
print).
|
|
21
|
Caruso G, Tomao F, Parma G, Lapresa M,
Multinu F, Palaia I, Aletti G and Colombo N: Poly (ADP-ribose)
polymerase inhibitors (PARPi) in ovarian cancer: Lessons learned
and future directions. Int J Gynecol Cancer. 33:431–443.
2023.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Rios-Doria E, Momeni-Boroujeni A, Friedman
CF, Selenica P, Zhou Q, Wu M, Marra A, Leitao MM Jr, Iasonos A,
Alektiar KM, et al: Integration of clinical sequencing and
immunohistochemistry for the molecular classification of
endometrial carcinoma. Gynecol Oncol. 174:262–272. 2023.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Passarelli A, Ventriglia J, Pisano C,
Cecere SC, Napoli MD, Rossetti S, Tambaro R, Tarotto L, Fiore F,
Farolfi A, et al: The way to precision medicine in gynecologic
cancers: The first case report of an exceptional response to
alpelisib in a PIK3CA-mutated endometrial cancer. Front Oncol.
12(1088962)2023.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Li J, Xue X, Zhang Y, Ding F, Wu W, Liu C,
Xu Y, Chen H, Ou Q, Shao Y, et al: The differences in immune
features and genomic profiling between squamous cell carcinoma and
adenocarcinoma-A multi-center study in Chinese patients with
uterine cervical cancer. Gynecol Oncol. 175:133–141.
2023.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Song Y, Bi Z, Liu Y, Qin F, Wei Y and Wei
X: Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer:
Current status in clinical trials. Genes Dis. 10:76–88.
2022.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Tewari KS, Sill MW, Long HJ III, Penson
RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao
MM, et al: Improved survival with bevacizumab in advanced cervical
cancer. N Engl J Med. 370:734–743. 2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Friedman CF, Ravichandran V, Miller K,
Vanderbilt C, Zhou Q, Iasonos A, Vivek M, Mishra P, Leitao MM Jr,
Broach V, et al: Assessing the genomic landscape of cervical
cancers: Clinical opportunities and therapeutic targets. Clin
Cancer Res. 29:4660–4668. 2023.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Jenkins TM and Mills AM: Putative
precancerous lesions of vulvar squamous cell carcinoma. Semin Diagn
Pathol. 38:27–36. 2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Ferrandina G, Palluzzi E, Gallotta V,
Gambacorta MA, Autorino R, Turco LC, Macchia G, Cosentino F, Gui B,
Mattoli MV, et al: Neo-adjuvant platinum-based chemotherapy
followed by chemoradiation and radical surgery in locally advanced
cervical cancer (Lacc) patients: A phase II study. Eur J Surg
Oncol. 44:1062–1068. 2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Pourmasoumi P, Moradi A and Bayat M:
BRCA1/2 mutations and breast/ovarian cancer risk: A new insights
review. Reprod Sci: Aug 6, 2024 (Epub ahead of print).
|
|
31
|
Qu Y, Qin S, Yang Z, Li Z, Liang Q, Long
T, Wang W, Zeng D, Zhao Q, Dai Z, et al: Targeting the DNA repair
pathway for breast cancer therapy: Beyond the molecular subtypes.
Biomed Pharmacother. 169(115877)2023.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Telli ML, Timms KM, Reid J, Hennessy B,
Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM, et
al: Homologous recombination deficiency (HRD) score predicts
response to platinum-containing neoadjuvant chemotherapy in
patients with triple-negative breast cancer. Clin Cancer Res.
22:3764–3773. 2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Moore K, Colombo N, Scambia G, Kim BG,
Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke
GS, et al: Maintenance olaparib in patients with newly diagnosed
advanced ovarian cancer. N Engl J Med. 379:2495–2505.
2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Mirza MR, Monk BJ, Herrstedt J, Oza AM,
Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I,
et al: Niraparib maintenance therapy in platinum-sensitive,
recurrent ovarian cancer. N Engl J Med. 375:2154–2164.
2016.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Li X and Zou L: BRCAness, DNA gaps, and
gain and loss of PARP inhibitor-induced synthetic lethality. J Clin
Invest. 134(e181062)2024.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Guo Z, Zhang R, Yang AG and Zheng G:
Diversity of immune checkpoints in cancer immunotherapy. Front
Immunol. 14(1121285)2023.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Aravantinou-Fatorou A, Andrikopoulou A,
Liontos M, Fiste O, Georgakopoulou VE, Dimopoulos MA,
Gavriatopoulou M and Zagouri F: Pembrolizumab in endometrial
cancer: Where we stand now. Oncol Lett. 22(821)2021.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Hamanishi J, Mandai M, Ikeda T, Minami M,
Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S,
et al: Safety and antitumor activity of anti-PD-1 antibody,
nivolumab, in patients with platinum-resistant ovarian cancer. J
Clin Oncol. 33:4015–4022. 2015.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Wang YM, Cai W, Xue QM, Zhang JY, Zhou L,
Xiong SY and Deng H: Prognostic role of different PD-L1 expression
patterns and tumor-infiltrating lymphocytes in high-grade serous
ovarian cancer: A systematic review and meta-analysis. Front
Immunol. 14(1234894)2023.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Andrikopoulou A, Liontos M, Skafida E,
Koutsoukos K, Apostolidou K, Kaparelou M, Rouvalis A, Bletsa G,
Dimopoulos MA and Zagouri F: Pembrolizumab in combination with
bevacizumab and oral cyclophosphamide in heavily pre-treated
platinum-resistant ovarian cancer. Int J Gynecol Cancer.
33:571–576. 2023.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Pujade-Lauraine E, Fujiwara K, Ledermann
JA, Oza AM, Kristeleit R, Ray-Coquard IL, Richardson GE, Sessa C,
Yonemori K, Banerjee S, et al: Avelumab alone or in combination
with chemotherapy versus chemotherapy alone in platinum-resistant
or platinum-refractory ovarian cancer (JAVELIN ovarian 200): An
open-label, three-arm, randomised, phase 3 study. Lancet Oncol.
22:1034–1046. 2021.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Howitt BE, Shukla SA, Sholl LM,
Ritterhouse LL, Watkins JC, Rodig S, Stover E, Strickland KC,
D'Andrea AD, Wu CJ, et al: Association of polymerase e-mutated and
microsatellite-instable endometrial cancers with neoantigen load,
number of tumor-infiltrating lymphocytes, and expression of PD-1
and PD-L1. JAMA Oncol. 1:1319–1323. 2015.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Zhang C, Wang M and Wu Y: Features of the
immunosuppressive tumor microenvironment in endometrial cancer
based on molecular subtype. Front Oncol. 13(1278863)2023.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Le DT, Durham JN, Smith KN, Wang H,
Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et
al: Mismatch repair deficiency predicts response of solid tumors to
PD-1 blockade. Science. 357:409–413. 2017.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Heeren AM, Punt S, Bleeker MC,
Gaarenstroom KN, van der Velden J, Kenter GG, de Gruijl TD and
Jordanova ES: Prognostic effect of different PD-L1 expression
patterns in squamous cell carcinoma and adenocarcinoma of the
cervix. Mod Pathol. 29:753–763. 2016.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Frenel JS, Le Tourneau C, O'Neil B, Ott
PA, Piha-Paul SA, Gomez-Roca C, van Brummelen EMJ, Rugo HS, Thomas
S, Saraf S, et al: Safety and efficacy of pembrolizumab in
advanced, programmed death ligand 1-positive cervical cancer:
Results from the phase Ib KEYNOTE-028 trial. J Clin Oncol.
35:4035–4041. 2017.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Choschzick M, Gut A and Fink D: PD-L1
receptor expression in vulvar carcinomas is HPV-independent.
Virchows Arch. 473:513–516. 2018.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Borella F, Preti M, Bertero L, Collemi G,
Castellano I, Cassoni P, Cosma S, Carosso AR, Bevilacqua F, Gallio
N, et al: Is there a place for immune checkpoint inhibitors in
vulvar neoplasms? A state of the art review. Int J Mol Sci.
22(190)2020.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Praiss A, Navitski A, Cohen S,
Tessier-Cloutier B, Broach V and O'Cearbhaill RE: Immunotherapy for
recurrent or metastatic vulvar carcinoma: A case report and review
of current guidelines. Gynecol Oncol Rep. 41(100982)2022.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Xu Y, Xiong F, Li H, Zheng H, Jiang J, Li
Q, Li G, Zhao W, Li R, Li J, et al: Biomarker-driven targeted
therapy in patients with recurrent platinum-resistant epithelial
ovarian cancer (BRIGHT): Protocol for an open-label, multicenter,
umbrella study. Int J Gynecol Cancer. 34:1461–1465. 2024.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Lee JY, Kim BG, Kim JW, Lee JB, Park E,
Joung JG, Kim S, Choi CH and Kim HS: Korean Gynecologic Oncology
Group (KGOG) investigators. Biomarker-guided targeted therapy in
platinum-resistant ovarian cancer (AMBITION; KGOG 3045): A
multicentre, open-label, five-arm, uncontrolled, umbrella trial. J
Gynecol Oncol. 33(e45)2022.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Ray-Coquard I, Pautier P, Pignata S, Pérol
D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N,
Mäenpää J, et al: Olaparib plus bevacizumab as first-line
maintenance in ovarian cancer. N Engl J Med. 381:2416–2428.
2019.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Marabelle A, Le DT, Ascierto PA, Di
Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M,
Penel N, Hansen AR, et al: Efficacy of pembrolizumab in patients
with noncolorectal high microsatellite instability/mismatch
repair-deficient cancer: Results from the phase II KEYNOTE-158
study. J Clin Oncol. 38:1–10. 2020.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Heery CR, O'Sullivan-Coyne G, Madan RA,
Cordes L, Rajan A, Rauckhorst M, Lamping E, Oyelakin I, Marté JL,
Lepone LM, et al: Avelumab for metastatic or locally advanced
previously treated solid tumours (JAVELIN solid tumor): A phase 1a,
multicohort, dose-escalation trial. Lancet Oncol. 18:587–598.
2017.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Makker V, Taylor MH, Aghajanian C, Oaknin
A, Mier J, Cohn AL, Romeo M, Bratos R, Brose MS, DiSimone C, et al:
Lenvatinib plus pembrolizumab in patients with advanced endometrial
cancer. J Clin Oncol. 38:2981–2992. 2020.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Makker V, Colombo N, Casado Herráez A,
Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay
S, Ray-Coquard I, et al: Lenvatinib plus pembrolizumab for advanced
endometrial cancer. N Engl J Med. 386:437–448. 2022.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Tewari KS, Sill MW, Penson RT, Huang H,
Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael
HE, et al: Bevacizumab for advanced cervical cancer: Final overall
survival and adverse event analysis of a randomised, controlled,
open-label, phase 3 trial (gynecologic oncology group 240). Lancet.
390:1654–1663. 2017.PubMed/NCBI View Article : Google Scholar
|
|
58
|
How JA, Jazaeri AA, Soliman PT, Fleming
ND, Gong J, Piha-Paul SA, Janku F, Stephen B and Naing A:
Pembrolizumab in vaginal and vulvar squamous cell carcinoma: A case
series from a phase II basket trial. Sci Rep.
11(3667)2021.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Naumann RW, Hollebecque A, Meyer T, Devlin
MJ, Oaknin A, Kerger J, López-Picazo JM, Machiels JP, Delord JP,
Evans TRJ, et al: Safety and efficacy of nivolumab monotherapy in
recurrent or metastatic cervical, vaginal, or vulvar carcinoma:
Results from the phase I/II CheckMate 358 trial. J Clin Oncol.
37:2825–2834. 2019.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Zhao M, Qiu S, Wu X, Miao P, Jiang Z, Zhu
T, Xu X, Zhu Y, Zhang B, Yuan D, et al: Efficacy and safety of
niraparib as first-line maintenance treatment for patients with
advanced ovarian cancer: Real-world data from a multicenter study
in China. Target Oncol. 18:869–883. 2023.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Simmons D, Blank S, Nagar S, Nham T, Long
G, Davis K, Wetherill G, Munley J and McLaurin K: Real-world
evaluation of PARP inhibitor tolerability in advanced ovarian
cancer: Retrospective US cohort study (2209). Gynecologic Oncology.
176 (Suppl 1):S262–S263. 2023.
|
|
62
|
Zhang N, Zheng H, Gao Y, Shu T, Wang H and
Cai Y: A real-world study of treatment patterns following disease
progression in epithelial ovarian cancer patients undergoing
poly-ADP-ribose polymerase inhibitor maintenance therapy. J Ovarian
Res. 17(55)2024.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Huepenbecker S, Meyer LA, Craft M, Chan
JK, Craggs C, Lambert P and Lin YG: Real-world use of immune
checkpoint inhibitors in advanced or recurrent endometrial cancer.
Int J Gynecol Cancer. (ijgc-2024-005541)2024.PubMed/NCBI View Article : Google Scholar : (Epub ahead of
print).
|
|
64
|
Testa U, Petrucci E, Pasquini L, Castelli
G and Pelosi E: Ovarian cancers: Genetic abnormalities, tumor
heterogeneity and progression, clonal evolution and cancer stem
cells. Medicines (Basel). 5(16)2018.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Kotnik EN, Mullen MM, Spies NC, Li T,
Inkman M, Zhang J, Martins-Rodrigues F, Hagemann IS, McCourt CK,
Thaker PH, et al: Genetic characterization of primary and
metastatic high-grade serous ovarian cancer tumors reveals distinct
features associated with survival. Commun Biol.
6(688)2023.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Lliberos C, Richardson G and Papa A:
Oncogenic pathways and targeted therapies in ovarian cancer.
Biomolecules. 14(585)2024.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Pešut E, Đukić A, Lulić L, Skelin J, Šimić
I, Milutin Gašperov N, Tomaić V, Sabol I and Grce M: Human
papillomaviruses-associated cancers: An update of current
knowledge. Viruses. 13(2234)2021.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Van Arsdale A, Turker L, Chang YC, Gould
J, Harmon B, Maggi EC, Meshcheryakova O, Brown MP, Luong D, Van
Doorslaer K, et al: Structure and transcription of integrated HPV
DNA in vulvar carcinomas. NPJ Genom Med. 9(35)2024.PubMed/NCBI View Article : Google Scholar
|
